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Introduction: In the phase II/III KEYNOTE-010 study
(ClinicalTrials.gov, NCT01905657), pembrolizumab signiﬁ-
cantly prolonged overall survival over docetaxel in patients
with previously treated, programmed death ligand
1–expressing (tumor proportion score  1%), advanced
NSCLC. Health-related quality of life (HRQoL) results are
reported here.
Methods: Patients were randomized 1:1:1 to pem-
brolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75
mg/m2 every 3 weeks. HRQoL was assessed using European
Organisation for Research and Treatment of Cancer
(EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30),
EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key
analyses included mean baseline-to-week-12 change in
global health status (GHS)/quality of life (QoL) score,
functioning and symptom domains, and time to deteriora-
tion in a QLQ-LC13 composite endpoint of cough, dyspnea,
and chest pain.
Results: Patient reported outcomes compliance was high
across all three instruments. Pembrolizumab was associ-
ated with better QLQ-C30 GHS/QoL scores from baseline to
12 weeks than docetaxel, regardless of pembrolizumab dose
or tumor proportion score status (not signiﬁcant).
Compared with docetaxel, fewer pembrolizumab-treated
patients had “deteriorated” status and more had
“improved” status in GHS/QoL. Nominally signiﬁcant
improvement was reported in many EORTC symptom do-
mains with pembrolizumab, and nominally signiﬁcant
worsening was reported with docetaxel. Signiﬁcant pro-
longation in true time to deterioration for the QLQ-LC13
composite endpoint emerged for pembrolizumab 10 mg/
kg compared to docetaxel (nominal two-sided p ¼ 0.03), but
not for the 2-mg/kg dose.
Conclusions: These ﬁndings suggest that HRQoL and
symptoms are maintained or improved to a greater degree
with pembrolizumab than with docetaxel in this NSCLC
patient population.
 2019 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
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EORTC QLQ-LC13Introduction
Single-agent docetaxel is a U.S. Food and Drug
Administration–approved choice for chemotherapy
following progression on a platinum-based combination
depending on improvement in survival, time to symptom
deterioration, and pain, although response rates are
generally low and the beneﬁt is short-lived.1 Nonethe-
less, docetaxel has become the standard comparator inmultiple clinical trials, and improvements upon it have
generally been marginal, with limited capture of quality
of life (QoL) data.2
Some tumors, including NSCLC, have been found
to express the programmed death-ligand 1 (PD-L1),
which enables them to exploit the programmed death 1
(PD-1):PD-L1 pathway to evade immune surveillance,
thus allowing them to grow and proliferate unchecked.3
The humanized monoclonal anti–PD-1 antibody pem-
brolizumab has shown signiﬁcant efﬁcacy as a mono-
therapy in patients with previously treated, advanced
NSCLC with a PD-L1 tumor proportion score [TPS]
greater than or equal to 1% in the KEYNOTE-010 study
(N ¼ 1034; ClinicalTrials.gov, NCT01905657).4 At a dose
of 2 mg/kg, pembrolizumab was also found to improve
overall survival compared with standard-of-care (doce-
taxel 75 mg/m2; hazard ratio [HR]: 0.71, 95% conﬁdence
interval [CI]: 0.58–0.88, p ¼ 0.0008) in patients with PD-
L1 TPS greater than or equal to 1% (10.4 months [95%
CI: 9.4–11.9 months] versus 8.5 months [95% CI, 7.5–9.8
months]).4 Lung indications for which pembrolizumab is
currently approved include metastatic NSCLC with PD-
L1 expression (TPS  1%) and disease progression on
or after platinum-containing chemotherapy, metastatic
NSCLC with high PD-L1 expression (TPS  50%) and no
prior systemic chemotherapy, in combination with
pemetrexed and carboplatin for previously untreated
metastatic, nonsquamous NSCLC, and in combination
with carboplatin and either paclitaxel or nab-paclitaxel
for previously untreated metastatic, squamous NSCLC.5-7
In addition to efﬁcacy, the tolerability of treatment
and impact on health-related quality of life (HRQoL) are
very important considerations for patients with cancer.
The effects of pembrolizumab and docetaxel on HRQoL
were evaluated in the present study using three patient-
reported outcomes (PRO) instruments that have been
widely used in phase III NSCLC trials: the European
Organization for Research and Treatment of Cancer
(EORTC) Quality of Life Questionnaire (QLQ) Core 30
(C30), EORTC QLQ Lung Cancer 13 (EORTC QLQ-LC13),
and the EuroQoL ﬁve dimensions, three-level question-
naire (EQ-5D-3L).8-11Materials and Methods
Study Design and Participants
KEYNOTE-010 was an international, open-label,
phase II/III study of pembrolizumab versus docetaxel
in which 1034 patients with previously treated advanced
NSCLC with PD-L1–expressing tumors and disease pro-
gression after platinum-containing systemic therapy
were enrolled between August 28, 2013, and February
27, 2015.4 The study design and primary efﬁcacy and
safety data are published elsewhere.4 In brief, adult
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diagnosis of NSCLC, disease progression after 2 cycles or
more of platinum-doublet chemotherapy, and PD-L1
expression on greater than or equal to 1% of tumor
cells (i.e., TPS  1%) were randomized 1:1:1 to receive
either pembrolizumab at a dose of 2 or 10 mg/kg
intravenously every 3 weeks for a maximum of 24 months
(i.e., 35 cycles) or docetaxel intravenously at a dose of
75 mg/m2 every 3 weeks for the maximum number of
cycles permitted by local regulatory authorities.4
Tumor PD-L1 expression was assessed using
formalin-ﬁxed parafﬁn-embedded tissue at a central
laboratory with the PD-L1 IHC 22C3 pharmDx immu-
nohistochemistry assay (Dako, Carpinteria, California)
and using the murine 22C3 anti–human PD-L1 antibody
(Merck & Co., Inc., Kenilworth, New Jersey).4,12,13
Patients were stratiﬁed according to level of PD-L1
expression by TPS (TPS  50% vs. TPS 1% to 49%),
as well as Eastern Cooperative Oncology Group perfor-
mance status (0 vs. 1) and geographic region of enroll-
ment (East Asia vs. non–East Asia).4
The study was conducted in accordance with the
protocol, Good Clinical Practice guidelines, and the
Declaration of Helsinki. All patients provided written
informed consent.HRQoL Objectives, Instruments, and
Assessments
The pre-speciﬁed key analyses for HRQoL were mean
change from baseline to week 12 in the EORTC QLQ-C30
global health status (GHS) score and time to deteriora-
tion (TTD) in an EORTC QLQ-LC13 composite endpoint
of cough (question [Q]1), dyspnea (Q3–Q5), and chest
pain (Q10).14,15 Traditional TTD was deﬁned as the time
to ﬁrst onset of 10-point or more decrease from baseline
in any one of these three symptoms (traditional deteri-
oration).16 True deterioration was deﬁned as TTD in the
EORTC QLQ-LC13 composite endpoint as described
above with a conﬁrmatory second, adjacent 10-point or
more decrease from baseline (true deterioration).
Supportive HRQoL analyses included, but were not
limited to proportion of patients who were improved,
stable, or deteriorated for EORTC QLQ-C30 GHS/QoL
score, functioning, and symptom scales at week 12 ac-
cording to a 10-point or more change from baseline, and
longitudinal score changes from baseline to week 12 in
EORTC QLQ-C30 functioning and symptom scales and
EORTC QLQ-LC13 symptom scales.16 In this regard,
improved was deﬁned as a 10-point or greater increase
in functioning scale scores or a 10-point or greater
decrease in symptom scale scores, and deteriorated was
deﬁned as a 10-point or greater decrease in functioning
scale scores or a 10-point or greater increase insymptom scale scores. Health status for economic
modeling was assessed using the EQ-5D visual analog
scale (VAS).
The HRQoL instruments were administered elec-
tronically by trained personnel and completed by the
patients themselves in the following order: EQ-5D-3L,
EORTC QLQ-C30, and EORTC QLQ-LC13. Each instru-
ment was administered at the start of cycles 1, 2, 3, and
5, and every 4 cycles thereafter until discontinuation and
30-day safety assessment. Study sites were instructed to
make every effort to ensure that administration of
HRQoL instruments occurred before all other study
procedures.Statistical Analyses
EORTC QLQ-C30, EORTC QLQ-LC13, and EQ-5D-3L
data were summarized according to the pre-speciﬁed
exploratory analysis plan, using an HRQoL-speciﬁc full
analysis set that comprised all randomized patients who
received at least one dose of study medication and
completed at least one PRO instrument. Analyses were
performed for all patients (TPS  1%) and for those with
tumor PD-L1 TPS  50% in each treatment arm.
PRO completion and compliance were calculated
using the following deﬁnitions: PRO completion was
deﬁned as the proportion of patients who completed at
least one valid questionnaire at each visit among the
HRQoL full analysis set population. PRO compliance was
deﬁned as the proportion of patients who completed at
least one valid questionnaire among those who were
expected to complete each visit, thus excluding those
patients from the denominator who were missing certain
visits by design (e.g., due to death, discontinuation due to
progression, discontinuation due to adverse event [AE],
other discontinuation of treatment, translations not be-
ing available, or no visit being scheduled). Visits of
treatment discontinuation and safety follow-up were
mapped to different timepoints according to the actual
visit time window.
Linear transformation was applied to standardize
raw scores to a range of 0 to 100.8 Mixed-effects models
based on the missing-at-random assumption were used
to assess changes in instrument score from baseline to
week 12. Kaplan-Meier plots, stratiﬁed log-rank tests,
and Cox proportional hazards models were used to
assess the TTD in the EORTC QLQ-LC13 composite
endpoint. Patients with no conﬁrmed decrease from
baseline were censored at the date of their last obser-
vation (right censoring rule). Descriptive analyses with
multiple imputation based on the missing-at-random
assumption yielded the proportion of patients with
improved, stable, or deteriorated EORTC QLQ-C30 GHS/
QoL and functional and symptom scales.
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The ﬁndings for patients treated with pembrolizumab
2 mg/kg who had TPS  1% were the focus, as this may
be the most clinically meaningful patient population
given the original approved indication for pem-
brolizumab in second-line NSCLC. Data for all patients
treated with pembrolizumab 10 mg/kg and those with
TPS  50% for either pembrolizumab dose can be found
in the supplementary materials.
PRO compliance was high across all three in-
struments (Supplementary Tables 1 through 3).
Compliance with EORTC QLQ-C30 at baseline was 96.1%
and 93.2% for the pembrolizumab 2 mg/kg and doce-
taxel treatment arms, respectively. Compliance with
EORTC QLQ-C30 at week 12 was 88.1% and 85.0%
among patients treated with pembrolizumab (2 mg/kg)
and docetaxel, respectively (Supplementary Table 1).
Instrument completion frequencies decreased over time
from baseline to week 36 as increasingly more patients
discontinued the study due to disease progression,
physician decision, AEs, or death. Findings were similar
for the EORTC QLQ-LC13 (Supplementary Table 2) and
EuroQoL-5D-3L instruments (Supplementary Table 3).
EORTC QLQ-C30
The baseline EORTC QLQ-C30 GHS/QoL score was
similar across treatment arms and PD-L1 TPS groups
(Table 1 and Supplementary Table 4); the mean score was
62.4 and 61.9 in patients treated with pembrolizumab
(2mg/kg) and docetaxel, respectively (Table 1). TherewasTable 1. Change From Baseline to Week 12 in EORTC QLQ-C30 G
Than or Equal to 1% Treated With Pembrolizumab 2 mg/kg or
Treatment Visit Category
Baseline na
Mean (SD)
Week 12 na
Mean (SD)
GHS/QoL change
from baseline
at week 12
nb
Mean (SD)
LS mean (95% CI)c
Difference in least squares
means (95% CI); p valued
Pembrolizum
docetaxel
aFor GHS and all functional domains, a positive change from baseline denotes
worsening HRQoL or functions.
bNumber of patients in full analysis set population with baseline and week 12 o
cBased on constrained longitudinal data analysis model, with the EORTC QLQ-C
stratiﬁcation factors (stratiﬁed by extent of tumoral PD-L1 expression [TPS  50%
East Asia], and Eastern Cooperative Oncology Group performance status [0 vs. 1])
a particular stratum, then that stratum is excluded from the treatment compa
dPairwise comparison of difference in LS means (95% CI).
EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Qu
related quality of life; LS, least squares; PD-L1, programmed death-ligand 1;
conﬁdence interval.less worsening from baseline to week 12 for the pem-
brolizumab 2 mg/kg treatment arm (-1.2; 95% conﬁdence
interval [CI]: -3.70 to 1.37) than for the docetaxel arm (-3.8;
95%CI: -6.74 to -0.90); the improvement inGHS/QoL score
for these patients compared to docetaxel was modest
(difference in least squares [LS]means: 2.7 points; 95% CI:
-1.1 to6.4; two-sidednominalp¼0.160)butnot signiﬁcant
(Table 1). In addition, among patients who stayed on
treatment and for whom PRO data were available beyond
week 12, the modest improvement in EORTC QLQ-C30
GHS/QoL score with pembrolizumab remained relatively
stable up to week 36 (Supplementary Fig. 1).
The proportion of patients with improvement in
EORTC QLQ-C30 GHS/QoL score up to week 12 was
larger for the pembrolizumab 2 mg/kg arm compared to
docetaxel (28.7% and 24.9%, respectively) (Fig. 1). In
addition, the proportion of patients with deterioration in
GHS/QoL score was smaller for the pembrolizumab
2 mg/kg arm than in the docetaxel arm (29.9% and
33.4%, respectively). With few exceptions, both the
pembrolizumab 2 mg/kg (Fig. 1) and 10 mg/kg
(Supplementary Fig. 2A and Supplementary Fig. 3)
treatment arms had a larger proportion of improved
EORTC QLQ-C30 functioning and symptom domains and
a smaller proportion of deteriorated functioning and
symptom domains compared with docetaxel up to week
12 (Fig. 1 and Supplementary Fig. 3).
Patients who received 2 mg/kg pembrolizumab had
nominally signiﬁcant improvement from baseline in
EORTC QLQ-C30 insomnia, appetite loss, andlobal Health Status in Patients With Tumor PD-L1 TPS Greater
Docetaxela
Pembrolizumab
2 mg/kg Q3W
Docetaxel
75 mg/m2 Q3W
312 266
62.4 (21.0) 61.9 (21.3)
222 162
65.3 (19.9) 62.4 (18.7)
212 146
-1.6 (23.3) -2.6 (19.7)
-1.2 (-3.70 to 1.37) -3.8 (-6.74 to -0.90)
ab 2 mg/kg vs.
75 mg/m2
2.7 (-1.05 to 6.36); p ¼ 0.1602
improving HRQoL or function, and a negative change from baseline denotes
bservations.
30 scores as the response variable and treatment by study visit interaction,
vs. TPS 1% to 49%], geographic region of the enrolling site [East Asia vs. non–
; if no patients are in one of the treatment groups involved in a comparison for
rison as covariates.
ality of Life Questionnaire Core 30; GHS, global health status; HRQoL, health-
Q3W, every 3 weeks; QoL, quality of life; TPS, tumor proportion score; CI,
PEMBROLIZUMAB 2 mg/kg
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Figure 1. Proportion of patients with deteriorated or
improved status in European Organisation for Research and
Treatment of Cancer Quality of Life Questionnaire–Core 30
scores at week 12 in patients with NSCLC tumor proportion
score 1% or greater. Multiple imputation based on missing at
random assumption was used.
May 2019 Effect of Pembrolizumab on HRQoL 797constipation (i.e., 95% CI does not cross baseline value)
(Fig. 2A). In contrast, patients receiving docetaxel re-
ported nominally signiﬁcant worsening from baseline in
fatigue, nausea and vomiting, and diarrhea (Fig. 2A).
Among patients without disease progression, there
was a slight improvement in GHS/QoL score from
baseline to week 12 for the pembrolizumab 2 mg/kg
arm, but a worsening in QoL score for docetaxel (Table 2,
Supplementary Table 5). Among patients with disease
progression, there was less worsening in GHS/QoL score
from baseline to week 12 for pembrolizumab 2 mg/kg
than for docetaxel (Table 2, Supplementary Table 5).
EORTC QLQ-LC13
There was no signiﬁcant difference in “traditional”
TTD in the QLQ-LC13 composite endpoint of cough,dyspnea, and chest pain between pembrolizumab and
docetaxel (Table 3, Supplementary Table 6); for patients
in the pembrolizumab 2 mg/kg arm, the HR was 1.12
(95% CI: 0.92–1.37; two-sided nominal p ¼ 0.2711)
compared to docetaxel (Table 3). Time to “true” deteri-
oration was prolonged for the pembrolizumab 2 mg/kg
dose group versus docetaxel (HR: 0.85 [0.69 to 1.06];
two-sided nominal p ¼ 0.1545) (Table 3), and for both
pembrolizumab dose groups versus docetaxel, regard-
less of TPS status, although the differences did not reach
statistical signiﬁcance in every instance (Supplementary
Table 6).
Patients who received pembrolizumab 2 mg/kg had
nominally signiﬁcant improvements from baseline in
symptoms of alopecia and chest pain, and notable
improvement in coughing (Fig. 2B). In contrast, pa-
tients in the docetaxel arm experienced nominally
signiﬁcant worsening from baseline in symptoms of
alopecia, peripheral neuropathy, sore mouth, and
dyspnea (Fig. 2B). Compared with docetaxel, nominally
signiﬁcant improvements were observed for alopecia,
peripheral neuropathy, and sore mouth among pa-
tients receiving pembrolizumab (2 mg/kg) (Fig. 2B).
Similar results were also observed for the pem-
brolizumab 10 mg/kg dose group (Supplementary
Fig. 2B).EQ-5D
The results of the EQ-5D VAS analyses were consis-
tent with those of the EORTC QLQ-C30 analyses
(Supplementary Table 7). The baseline EQ-5D VAS score
was similar across treatment arms and PD-L1 TPS
groups, at 69.8 and 67.5 for the patients with PD-L1 TPS
greater than or equal to 1% treated with pembrolizumab
(2 mg/kg) and docetaxel, respectively. There was slight
improvement from baseline to week 12 for the pem-
brolizumab 2 mg/kg treatment arm (1.5; 95% CI: -0.7 to
3.6) versus a reduction for the docetaxel arm (-1.3; 95%
CI: -3.8 to 1.3); the improvement in VAS score for these
patients compared to docetaxel was modest (difference
in LS means: 2.7 points; 95% CI: -0.4 to 5.8) but not
signiﬁcant (Supplementary Table 7).
Discussion
To our knowledge, this is the ﬁrst study to investigate
the effect of pembrolizumab on HRQoL in patients with
advanced NSCLC in the second-line setting. We found
that treatment with pembrolizumab resulted in a
numerically smaller reduction in the EORTC QLQ-C30
GHS/QoL score from baseline to week 12 (the esti-
mated time at which more than half of patients in the
docetaxel arm would have experienced disease pro-
gression).1 Although the difference between treatment
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Figure 2. Change from baseline to week 12 in (A) European Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire–Core 30 (EORTC QLQ-C30) and (B) European Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) symptoms in patients with programmed death-ligand 1 tumor proportion
score 1% or greater (full analysis set population) treated with pembrolizumab 2 mg/kg or docetaxel. Error bars are 95%
conﬁdence intervals. Q3W, every 3 weeks.
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gests less worsening in HRQoL with pembrolizumab
than with docetaxel in patients with previously treated,PD-L1–expressing NSCLC. EQ-5D VAS analyses yielded
similar ﬁndings. When improved and deteriorated status
was deﬁned as a 10-point change from baseline (as
Table 2. Change From Baseline to Week 12 in EORTC QLQ-C30 GHS by Disease Progression in Patients With PD-L1 TPS Greater
Than or Equal to 1% Treated With Pembrolizumab 2 mg/kg or Docetaxela
Pembrolizumab 2 mg/kg Q3W n ¼ 331 Docetaxel 75 mg/m2 Q3W n ¼ 291
Without PD, LS mean (95% CI)b 1.38 (-1.20 to 3.96) -1.72 (-4.62 to 1.19)
With PD, LS mean (95% CI)b -7.85 (-11.00 to -4.70) -10.95 (-14.47 to -7.42)
Difference by PD status, LS mean (95% CI)b -9.23 (-11.88 to -6.58)
aAssumes the PD effect is the same across different treatment arms.
bBased on constrained longitudinal data analysis model with the EORTC QLQ-C30 GHS scores as the response variable, and treatment by study visit interaction,
stratiﬁcation factors (extent of tumoral PD-L1 expression [PD-L1 TPS  50% vs. PD-L1 TPS 1% to 49%], geographic region of the enrolling site [East Asia vs. non–
East Asia], and Eastern Cooperative Oncology Group performance status [0 vs. 1]); if there were no patients in one of the treatment groups involved in a
comparison for a particular stratum, then that stratum was excluded from the treatment comparison) as covariates.
EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; GHS, global health status; PD, progressive
disease; PD-L1, programmed death-ligand 1; Q3W, every 3 weeks; TPS, tumor proportion score; LS, least squares; CI, conﬁdence interval.
May 2019 Effect of Pembrolizumab on HRQoL 799deﬁned above), the pembrolizumab (2 mg/kg) treatment
arm had a larger proportion of improved EORTC QLQ-
C30 GHS/QoL scores and functioning and symptom
domains and a smaller proportion of deteriorated
scores compared with docetaxel. Nominally signiﬁcant
improvement was reported in many symptom domains
with pembrolizumab, whereas nominally signiﬁcant
worsening was reported with docetaxel. Overall, the QoL
analysis reinforces the objective response rate and
progression-free survival results without showing any
unexpected detrimental effect regarding the known
safety proﬁle of pembrolizumab.
Long-term HRQoL data can be challenging to obtain
because PRO completion rates drop off over the course
of trials due to AEs, progression, and death (e.g., less
than 10% of patients in the docetaxel arm completed
PRO assessments at week 36). Following disease pro-
gression and discontinuation of treatment or the trial,
the feasibility of continuing to administer PRO assess-
ments that are tied to a clinic visit for receipt of study
treatment is low. In this study, PRO data were collected
post-progression by including an assessment at the 30-
day safety follow-up visit because this visit followed
treatment discontinuation primarily due to disease
progression.Table 3. Time to Composite Deterioration of Cough, Chest Pain
Greater Than or Equal to 1% Treated With Pembrolizumab 2 m
Pembrolizumab 2 mg/k
Traditional deteriorationa
Events, n (%) 219 (66.2)
Hazard ratio (95% CI); p valueb 1.12 (0.92 to 1.37); p ¼ 0
True deteriorationc
Events, n (%) 177 (53.5)
Hazard ratio (95% CI); p valueb 0.85 (0.69 to 1.06); p ¼ 0
aDeﬁned as time to ﬁrst onset of 10-point or more decrease from baseline.
bBased on Cox regression model with treatment as a covariate stratiﬁed by exten
of the enrolling site (East Asia vs. non–East Asia), and Eastern Cooperative On
treatment groups involved in a comparison for a particular stratum, then that s
cDeﬁned as time to ﬁrst onset of 10-point or more decrease from baseline, with
EORTC QLQ-LC13, European Organisation for Research and Treatment of Cance
ligand 1; Q3W, every 3 weeks; TPS, tumor proportion score; CI, conﬁdence inteAlthough novel treatment approaches for NSCLC such
as immune checkpoint inhibitors have brought with
them improved overall survival compared to standard-
of-care chemotherapies, these ﬁndings must be
weighed against any associated negative outcomes to
ensure that any clinical gains do not come at the expense
of intolerable reductions in HRQoL.4,17-25 There is
currently no information in the literature regarding the
HRQoL effects of pembrolizumab in NSCLC in the
second-line setting. In the ﬁrst-line setting, pem-
brolizumab monotherapy was associated with improved
HRQoL and prolonged TTD among patients with
advanced NSCLC with TPS greater than or equal to 50%
and without sensitizing EGFR/ALK receptor tyrosine
kinase (ALK) alterations (ﬁndings that concur with those
reported here for patients with TPS  50% receiving 2
mg/kg pembrolizumab).26 Additionally, pembrolizumab
in combination with pemetrexed and platinum main-
tained or improved HRQoL over placebo plus peme-
trexed and platinum among patients with metastatic
nonsquamous NSCLC and without sensitizing EGFR/
ALK alterations, irrespective of PD-L1 expression.27
Furthermore, HRQoL has been studied in patients with
ipilimumab-refractory or -naïve advanced melanoma
who received pembrolizumab in the KEYNOTE-002, and Dyspnea (EORTC QLQ-LC13) in Patients With PD-L1 TPS
g/kg or Docetaxel
g Q3W n ¼ 331 Docetaxel 75 mg/m2 Q3W n ¼ 291
170 (58.4)
.2711 Comparator
151 (51.9)
.1545 Comparator
t of tumoral PD-L1 expression (TPS  50% vs. TPS 1% to 49%), geographic region
cology Group performance status (0 vs. 1); if no patients are in one of the
tratum was excluded from the treatment comparison.
conﬁrmatory follow-up of 10-point or more decrease.
r Quality of Life Questionnaire Lung Cancer 13; PD-L1, programmed death-
rval.
800 Barlesi et al Journal of Thoracic Oncology Vol. 14 No. 5(NCT01704287) and KEYNOTE-006 (NCT01866319)
studies.28,29 The HRQoL ﬁndings of both were similar to
those presented here, namely that pembrolizumab was
well tolerated in patients with advanced melanoma, and
either improved or maintained HRQoL and symptoms
during treatment relative to either chemotherapy or
ipilimumab.28,29 Similar ﬁndings were also reported in
patients with previously treated advanced urothelial
cancer who received pembrolizumab versus docetaxel,
paclitaxel, or vinﬂunine in KEYNOTE-045
(NCT02256436).30
There has been some exploration of the HRQoL
effects of another anti–PD-1 agent — nivolumab — in
advanced malignancies, including NSCLC.17,22,31-33 In the
CheckMate 017 study of nivolumab versus docetaxel in
advanced NSCLC, the EQ-5D VAS instrument was used to
evaluate patient-reported health status every 4 and 3
weeks for nivolumab and docetaxel, respectively, for the
ﬁrst 6 months on treatment; then every 6 weeks; and
ﬁnally at two follow-up visits after treatment discon-
tinuation.33 From similar baseline scores, nivolumab
treatment was associated with clinically and statistically
signiﬁcant improvements in health status from baseline
relative to docetaxel.33 Furthermore, the TTD (as
measured by the Lung Cancer Symptom Scale, a global
HRQoL instrument) was longer in the nivolumab arm
than in those treated with docetaxel.17,33
Potential limitations of the current analysis include
concern that the EORTC QLQ-LC13 instrument may not
adequately reﬂect the experiences of patients who
receive therapies developed after its development in
1994, the fact that the treatment was open-label (which
could impact patients’ perception of QoL), and the
limited duration of follow-up.34 The appropriateness of
the HRQoL instruments may be mitigated in part
because many commonly occurring symptoms attributed
to immunotherapy, such as fatigue and gastrointestinal
symptoms, could be captured using the EORTC QLQ-C30
and EORTC QLQ-LC13 questionnaires.
In conclusion, the present ﬁndings suggest that
HRQoL and symptoms were either maintained or
improved to a greater degree with 2 mg/kg pem-
brolizumab than with docetaxel in this population of
patients with previously treated, PD-L1–expressing (TPS
 1%) advanced NSCLC.
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